PatientsVille.com Logo


Cyclophospham Medical Research Studies

Up-to-date List of Cyclophospham Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Cyclophospham Medical Research Studies

Rank Status Study
1 Recruiting Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
Condition: Hematologic Malignancies
Intervention: Drug: Cyclophosphamide
Outcome Measures: Cyclophosphamide Dose;   Resource Utilization
2 Recruiting Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, endoxan, prednisone;   Drug: lenalidomide, endoxan, prednisone
Outcome Measures: Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT);   phase 1 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT);   phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)
3 Recruiting Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children
Conditions: Renal Insufficiency;   Infection
Interventions: Drug: Low-dose intravenous Cyclophosphamide;   Drug: High-dose intravenous Cyclophosphamide
Outcome Measures: renal response;   infection
4 Recruiting Cyclophosphamide With or Without Veliparib in Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: veliparib;   Drug: Cyclophosphamide;   Other: placebo;   Other: laboratory biomarker analysis
Outcome Measures: Recommended phase II dose of veliparib that may be used with metronomic Cyclophosphamide;   Progression-free survival (PFS) according to RECIST version 1.1;   Clinical response (complete or partial response) according to RECIST version 1.1;   Overall survival;   MacroH2A1.1 expression levels (Phase II);   PARP1 expression status (Phase II)
5 Recruiting Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
Condition: HIV
Intervention: Genetic: SB-728-T
Outcome Measures: Treatment related Adverse Events on subjects who received Cyclophosphamide prior to SB-728-T infusion;   Effect of escalating doses of Cyclophosphamide on SB-728-T engraftment as measured by pentamer PCR;   Effect of SB-728-T on plasma HIV-1 RNA levels following HAART interruption;   Change in CD4+ T-cell counts in peripheral blood after treatment with SB-728-T
6 Not yet recruiting High-dose Cyclophosphamide for Severe Refractory Crohn Disease
Conditions: Crohn's Disease;   Crohn Disease
Intervention: Drug: High-dose Cyclophosphamide
Outcome Measures: Crohn's Symptoms: Drop in Crohn's Disease Activity Index (CDAI) of 100 Points;   Endoscopic Outcomes: Absence of Ulcers on Colonoscopy;   High-dose Cyclophosphamide (HDC)-Induced Remission;   HDC-Induced Mucosal Healing;   Molecular Mechanisms of High-dose Cyclophosphamide (HiCy) Therapy
7 Recruiting Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Oprozomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Cyclophosphamide
Outcome Measures: To establish the maximum tolerated dose (MTD) of oprozomib and dexamethasone administered in combination with lenalidomide or oral Cyclophosphamide;   To evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral Cyclophosphamide;   To estimate the overall response rate (ORR);   To estimate the complete response rate (CRR);   To evaluate population pharmacokinetic (PK) parameter estimates of oprozomib and variability in these estimates when administered in combination with lenalidomide and dexamethasone, or oral Cyclophosphamide and dexamethasone;   To estimate the duration of response (DOR);   To estimate progression-free survival (PFS)
8 Not yet recruiting Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Conditions: Acute Leukemias;   Chronic Leukemias;   Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia
Intervention: Drug: Busulfan/Cyclophosphamide
Outcome Measures: Overall survival;   Disease free survival
9 Recruiting Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant, Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Immunodeficiency or Noncancerous Inherited Disorders
Conditions: Aplastic Anemia;   Nonneoplastic Condition
Interventions: Drug: Cyclophosphamide;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Outcome Measures: Graft rejection/failure rate;   TRM;   Incidence of grade III/IV acute GVHD preceding diagnosis of chronic GVHD;   Proportion of patients who achieve greater than 5% donor T-cell chimerism
10 Recruiting Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Condition: Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Sapacitabine
Outcome Measure: Overall Response Rate (ORR)
11 Recruiting Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Cyclophosphamide
Outcome Measures: To determine the maximum tolerated dose (MTD) of CY (PO and IV) in combination with LEN/low-dose DEX;   To investigate the best objective response (EBMT criteria) to both treatment regimens;   To investigate safety and tolerability of both treatment regimens;   To investigate other efficacy parameters of both treatment regimens
12 Recruiting SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: SMAC mimetic LCL161;   Drug: Cyclophosphamide;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: quality-of-life assessment
Outcome Measures: Proportion of confirmed overall responses (stringent complete response [sCR], complete response [CR], very good partial response [VGPR], or partial response [PR]) with single agent SMAC mimetic LCL161;   Confirmed overall response rate with the addition of Cyclophosphamide;   Overall survival;   Event-free survival;   Incidence of adverse events graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
13 Recruiting Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
Conditions: Malignant Solid Tumour;   Breast Cancer Nos Metastatic Recurrent;   Neuropathy
Intervention: Drug: Eribulin in Combination w/ Cyclophosphamide
Outcome Measures: Phase Ib: 1. Maximum tolerated dose (MTD) of eribulin in combination with Cyclophosphamide in patients with any solid tumor;   Phase II 1. Clinical benefit (complete response, partial response, and stable disease) of the combination of eribulin and Cyclophosphamide in patients with advanced breast cancer;   Phase Ib: 1. Safety of treatment;   Phase Ib: 2. Dose Limiting Toxicity (DLT);   Phase Ib: 3. Pharmacokinetics (PK) and potential for drug-drug interaction;   Phase Ib: 4. Quality of life;   Phase Ib: 5. Pharmacodynamic, pharmacogenomic and response prediction biomarkers;   Phase II 1. Efficacy of drug combination in patients with advanced breast cancer including response rate, duration of response and time to progression;   Phase II 2. Safety of drug combination in expanded cohort - metastatic breast cancer;   Phase II 3. Quality of life endpoints;   Phase II 4. Pharmacodynamic, pharmacogenomic and response prediction biomarkers
14 Recruiting Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas
Condition: Pancreatic Cancer
Interventions: Drug: Cyclophosphamide;   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine;   Radiation: Stereotactic Body Radiation (SBRT);   Drug: FOLFIRINOX
Outcome Measures: Number of participants with adverse events as a measure of toxicity;   Survival;   Time to disease progression using immune correlates
15 Recruiting Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
Conditions: Systemic Sclerosis;   Scleroderma;   Interstitial Lung Disease;   Lung Fibrosis
Interventions: Drug: Cyclophosphamide;   Drug: Placebo
Outcome Measures: Forced vital capacity;   Mortality;   Progression free survival;   Carbon monoxide diffusing capacity (DLCO);   Treatment failure;   Walk test distance;   Dyspnea;   Health Assessment Questionnaire;   Quality of life;   Chest CT (computed tomography) scan
16 Recruiting Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
Conditions: Recurrent or Refractory Solid Tumors;   Ewing Sarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Osteosarcoma
Intervention: Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus Cyclophosphamide
Outcome Measures: To determine the Maximum Tolerated Dose (MTD) of MM-398 in combination with intravenous Cyclophosphamide by assessing the occurrence of dose limiting toxicities;   Measurement of plasma levels of study drug to determine the pharmacokinetic properties of MM-398 in combination with Cyclophosphamide
17 Recruiting Study of Myocet Plus Cyclophosphamide Plus Metformin Versus Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Cancer Patients
Condition: HER2-negative Metastatic Breast Cancer Patients
Interventions: Drug: Metformin + Myocet + Cyclophosphamide;   Drug: Myocet + Cyclophosphamide
Outcome Measures: progression-free survival (PFS);   Objective response rate;   Overall survival;   Progression free survival as function of Homa Index levels;   objective response rate as function of Homa Index levels;   overall survival as function of Homa Index levels;   patient metabolic profile (metabolic syndrome)
18 Recruiting Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
Condition: Pemphigus
Intervention: Drug: Rituximab and Cyclophosphamide IV
Outcome Measures: Study the clinical efficacy of IV rituximab vs IV rituximab and IV Cyclophosphamide combination for treatment of refractory pemphigus in terms of early and late end points as defined by the international pemphigus committee;   Study the characteristics of B cell depletion and repopulation following IV rituximab and combination of IV Cyclophosphamide with IV rituximab.
19 Recruiting Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Estrogen Receptor-negative Breast Cancer;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HER2-negative Breast Cancer;   Intraocular Lymphoma;   Male Breast Cancer;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Progesterone Receptor-negative Breast Cancer;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Breast Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Breast Cancer;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IIIC Breast Cancer;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Breast Cancer;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: veliparib;   Drug: Cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: MTD, defined as the dose level that no more than 2/6 or 1/3 patients experience DLT and at least 2/3 or 3/6 patients treated with next higher dose level will have had DLT;   Change in pharmacokinetic parameters;   Change in gammaH2AX levels (quantification of the time point of maximal DNA damage)
20 Recruiting Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Condition: Large Granular Lymphocytes Leukemia
Interventions: Drug: Methotrexate;   Drug: Cyclophosphamide
Outcome Measures: Complete response (CR);   overall response rate (ORR);   Hematological partial response (PR);   Progressive disease;   Time-to-relapse;   Molecular remission;   Adverse events rate;   Compliance;   relationship between the response to treatment and the phenotypic subtype

These studies may lead to new treatments and are adding insight into Cyclophospham etiology and treatment.

A major focus of Cyclophospham research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Cyclophospham